Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CelestaPro Numbing Cream is a topical local anesthetic formulation distributed by CelestaPro, a Korean aesthetic products platform. It is designed to provide temporary surface anesthesia prior to minimally invasive aesthetic and dermatological procedures, such as dermal filler injections, botulinum toxin applications, microneedling, and laser therapy. The product typically contains lidocaine as its primary active ingredient, which functions by blocking voltage-gated sodium channels in sensory neurons. This action prevents the initiation and conduction of nerve impulses, effectively inhibiting the transmission of pain signals from the skin surface to the central nervous system. It is marketed for professional use in clinical and aesthetic settings to enhance patient comfort during procedural interventions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CelestaPro Numbing Cream.